Clinical trials: Tamoxifen
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
This is a phase II, randomized, double-blinded, placebo-controlled trial designed to evaluate the efficacy of fezolinetant (45 mg a day) vs.
- Trial name
- NCT06917313
- Testing
- Fezolinetant
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Yale University
Breast Cancer, Locoregional Recurrence
Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)
The JCOG2313 trial is a multicenter, randomized, phase III study designed to evaluate the efficacy and safety of adjuvant abemaciclib in combination with endocrine therapy versus endocrine therapy alone in patients with hormone…
- Conditions
- Breast Cancer, Locoregional Recurrence, Abemaciclib, Endocrine Therapy
- Trial name
- AURA (NCT07190443)
- Testing
- Endocrine therapy + Abemaciclib, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
- Where
- Japan
- Volunteers
- 290 people
- Sponsor
- Japanese Foundation for Cancer Research
Benign Breast Disease, Fibrocystic Disease of Breast
Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer
The purpose of the study is to determine the efficacy and relapse rate of low dose, short duration treatment with tamoxifen in benign breast disease amenable to hormonal therapy with respect to etiology and estrogen receptor…
- Conditions
- Benign Breast Disease, Fibrocystic Disease of Breast, Fibroadenoma, Mastalgia
- Trial name
- NCT00999921
- Testing
- Tamoxifen, Evening Primrose Oil
- Where
- India
- Volunteers
- 256 people
- Sponsor
- Medical College and Hospital Kolkata
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby tissue or lymph nodes or other parts of the body…
- Conditions
- Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7
- Trial name
- NCT02311933
- Testing
- Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 559 sites in United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Intraocular Melanoma
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00489944
- Testing
- cisplatin, sunitinib malate, tamoxifen citrate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
Schizophrenia, Schizoaffective Disorder
Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder
The objective of the study is to evaluate the efficacy of raloxifene compared to placebo, as add-on to anti-psychotics in the treatment of post menopausal patients with schizophrenia.
- Trial name
- RAL-S-01 (NCT01280305)
- Testing
- raloxifene
- Where
- 13 sites in Israel, Romania
- Volunteers
- 200 people
- Sponsor
- Sheba Medical Center
Postemenopusal Women With Osteopenia
Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia
Osteoporosis is a very strong predictor of fractures with low BMD, but more than half of osteoporotic fractures actually occur in the osteopenic patient group.
- Trial name
- NCT05386784
- Testing
- Raloxifene plus cholecalciferol, Cholecalciferol
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- Yonsei University
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
This phase II trial is studying how well giving entinostat and anastrozole together works in treating postmenopausal women with triple-negative breast cancer that can be removed by surgery.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer
- Trial name
- 0927GCC (NCT01234532)
- Testing
- entinostat, anastrozole, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore
Breast Cancer, Quality of Life
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
The aim of this prospective study is to investigate quality of life and oncologic outcomes in low-risk elderly breast cancer patients randomized to adjuvant therapy with accelerated partial breast irradiation (APBI) alone or…
- Trial name
- CAMERAN (NCT05472792)
- Testing
- Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Diseases, Breast Neoplasms
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
This study is a multicenter, prospective, randomized, open-label clinical study to assess the efficacy and safety of endocrine combined with different doses and treatment duration of darisenatide adjuvant therapy in HR +/HER2…
- Conditions
- Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases
- Trial name
- NCT07581834
- Testing
- Dalpiciclib 125mg, Dalpiciclib 100mg, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
- Where
- 2 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Fujian Cancer Hospital
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
The purpose of the Phase Ib is to: 1. determine the recommended dose of LEE011 in combination with a standard dose of letrozole as well as to provide additional safety and anti-tumor activity data in Asian non-Japanese patients…
- Trial name
- NCT02333370
- Testing
- LEE011, Letrozole, Tamoxifen
- Where
- 15 sites in Hong Kong, Japan and 1 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Metastatic Disease
Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
Primary objectives of this study is to evaluate the effects of CYP2D6 genotypes on time to progression after tamoxifen treatment in pre- or postmenopausal women with metastatic breast cancer.
- Trial name
- NCT00532454
- Testing
- Tamoxifen
- Where
- 2 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- National Cancer Center, Korea
Breast Cancer
Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of tamoxifen may be effective in preventing breast cancer.
- Trial name
- NCT00096369
- Testing
- tamoxifen citrate
- Where
- 4 sites in United States
- Volunteers
- 130 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
The purpose of this study is to compare tamoxifen, versus a newer treatment, ARIMIDEX, which we already know to be well tolerated.
- Trial name
- NCT00232661
- Testing
- ARIMIDEX (anastrazole), NOLVADEX (tamoxifen)
- Where
- 79 sites in United States, Belgium and 8 more
- Volunteers
- 452 people
- Sponsor
- AstraZeneca
Uterine Cervical Neoplasms
A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix
The investigators design a phase 2, open labeled, randomized trial of Tamoxifen (20 mg/day) and Letrozole (2.5 mg) in treatment of squamous carcinoma of the cervix.
- Trial name
- TGOG1005 (NCT02482740)
- Testing
- Letrozole, tamoxifen
- Where
- 7 sites in Taiwan
- Volunteers
- 44 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Cancer
Sexual Coercion in Breast Cancer Patients Treated With Luteinizing Hormone-Releasing Hormone Agonists (LHRHa )
The use of luteinizing hormone-releasing hormone agonists(LHRHa) to suppress ovarian function is a common strategy for treating premenopausal, hormone receptor-positive breast cancer.
- Trial name
- LHRHa (NCT06840847)
- Testing
- Sexual Coercion
- Where
- Turkey (Türkiye)
- Volunteers
- 79 people
- Sponsor
- Canan Kas
Breast Cancer
Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer
Post operative adjuvant chemotherapy followed by adjuvant Tamoxifen vs nil for patients with operable breast cancer
- Trial name
- NCT00538330
- Testing
- Tamoxifen
- Volunteers
- 2,000 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Breast Cancer
An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer
The purpose of this indirect treatment comparison (ITC) was to generate comparative evidence on the effectiveness and safety in premenopausal women of ribociclib+Non-steroidal Aromatase Inhibitor (NSAI)+Ovarian Function…
- Trial name
- IRINA (NCT07072013)
- Testing
- ribociclib
- Where
- Germany
- Volunteers
- 1,937 people
- Sponsor
- Novartis Pharmaceuticals
Hypogonadism, Prostate Cancer
Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients
Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in…
- Trial name
- REVIVE (NCT07535905)
- Testing
- Tamoxifen
- Where
- Canada
- Volunteers
- 96 people
- Sponsor
- University Health Network, Toronto
Breast Cancer
Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002579
- Testing
- CMF regimen, cyclophosphamide, fluorouracil
- Where
- 10 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Scottish Cancer Therapy Network